SCHEMBL3520224

SCHEMBL3520224

COC(=O)CCC#Cc1cc(C(F)(F)F)ccc1NS(=O)(=O)c1ccc2sc(C)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.45
ALDH1A1 P00352 3/20 0.44
POLB P06746 2/20 0.42
LMNA P02545 3/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 2/20 0.40
ALOX15 P16050 1/20 0.40
PKM P14618 2/20 0.38
TP53 P04637 2/20 0.37
USP2 O75604 2/20 0.37
USP8 P40818 2/20 0.37
MAPT P10636 1/20 0.37
KDM1A O60341 1/20 0.37
DYRK1A Q13627 1/20 0.36
SCN9A Q15858 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CCR2 P41597 1/20 0.35
NOD2 Q9HC29 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527568 0.95 TRPV1 (0.43) TRPV1ALDH1A1POLBLMNAMAPK1
SCHEMBL3522354 0.94 LMNA (0.46) ALDH1A1LMNAMAPK1HTTALOX15
SCHEMBL3526140 0.85 TRPV1 (0.45) TRPV1ALDH1A1POLBLMNAMAPK1
SCHEMBL3521451 0.85 EPHX2 (0.42) TRPV1ALDH1A1POLBLMNAHTT
SCHEMBL3523775 0.83 CCKBR (0.42) POLBTP53USP2USP8MAPT
SCHEMBL3528051 0.83 ALDH1A1 (0.45) ALDH1A1POLBLMNAMAPK1HTT
SCHEMBL3525396 0.83 ALDH1A1 (0.44) ALDH1A1POLBPKMKDM1ASCN9A
SCHEMBL3522958 0.83 DYRK1A (0.52) MAPK1USP2USP8DYRK1A
SCHEMBL3524774 0.82 ALDH1A1 (0.41) ALDH1A1POLBLMNAMAPTKDM1A
SCHEMBL3524894 0.78 ALDH1A1 (0.42) ALDH1A1POLBPKMKDM1ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436040-B2 Method of treating conditions involving PPAR-receptors with indole compounds LABORATOIRES FOURNIER S.A. (FR) 2013-05-07 US disclosed
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds LABORATORIES FOURNIER S.A. (FR) 2010-11-11 US disclosed
US-7795297-B2 Indole compounds, method of preparing them and uses thereof LABORATORIES FOURNIER S.A. (FR) 2010-09-14 US disclosed
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153816-A1 Indole Compounds, Method of Preparing Them and Uses Thereof LIPG, GPR119, IAPP TRPV1 1619/4885ALDH1A1 1607/4885POLB 4410/4885
US-20100286137-A1 Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds GPR119, PPARA, PPARG TRPV1 631/4885ALDH1A1 1453/4885POLB 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.